HI
TARA icon

HBK Investments’s Protara Therapeutics TARA Stock Holding History

HBK Investments’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-20,000
Closed -$106K – 231
2024
Q4 		$106K Buy
+20,000
New +$64.6K ﹤0.01% 195

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

HBK Investments's TARA Position: Q1 2025 in Review

HBK Investments sold out of Protara Therapeutics (TARA) in Q1 2025, closing a stake of 20,000 shares — an estimated $106K sold.

HBK Investments first reported a position in TARA in Q4 2024 and held it in 1 quarter. The position peaked at $106K in Q4 2024. 59 funds tracked by Wall St. Rank hold TARA as of Q1 2025.

  • HBK Investments reported no remaining Protara Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HBK Investments sold 20,000 Protara Therapeutics shares in Q1 2025, an estimated $106K.
  • HBK Investments first reported a position in Protara Therapeutics in Q4 2024 and held it in 1 quarter.
  • HBK Investments's Protara Therapeutics position peaked at $106K in Q4 2024.
  • 59 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2025.

Based on HBK Investments's 13F filing for Q1 2025, filed 15 May 2025.